XML 48 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Organization and Description of Business - Narrative (Details)
$ / shares in Units, shares in Thousands
3 Months Ended 12 Months Ended
May 07, 2019
USD ($)
$ / shares
shares
Apr. 09, 2018
Mar. 31, 2020
USD ($)
delivery
financial_institution
diseaseAreas
segment
$ / shares
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Cash and Cash Equivalents [Line Items]              
Number of operating segments | segment     1        
Number of disease areas with genomic testing | diseaseAreas     4        
Prior period reclassification adjustment           $ 212,000  
Number of shares issued and sold (in shares) | shares 6,325            
Price per share (in usd per share) | $ / shares $ 23.25            
Proceeds from issuance of common stock $ 137,800,000            
Stock issuance costs $ 9,200,000            
Percent of principal amount needed to be collateralized by U.S. treasury and agency securities     102.00%        
Number of major financial institutions with which the company's cash and cash equivalents are deposited (in financial institutions) | financial_institution     1        
Restricted cash     $ 603,000       $ 603,000
Loss from operations     $ (12,200,000)     $ (2,067,000)  
Net income (loss) per common share, basic and diluted (in usd per share) | $ / shares     $ (0.24)     $ (0.05)  
Number of tissue sample deliveries (in deliveries) | delivery     0        
Revenue     $ 31,122,000     $ 29,529,000  
Right-of-use assets - operating lease     8,576,000       8,808,000
Operating lease, liability     12,582,000        
Headquarters and laboratory facilities, South San Francisco, lease signed April 2015              
Cash and Cash Equivalents [Line Items]              
Restricted cash     603,000       603,000
Biopharmaceutical Company              
Cash and Cash Equivalents [Line Items]              
Deferred revenue     0       0
Tissue Samples              
Cash and Cash Equivalents [Line Items]              
Contract with customer, revenue recognized     90,000        
Contract agreement term   1 year          
Automatic renewal period of contract agreement   1 year          
Termination period   90 days          
Revenue     3,409,000     0  
Other Services              
Cash and Cash Equivalents [Line Items]              
Contract with customer, revenue recognized       $ 250,000 $ 250,000 250,000  
Testing              
Cash and Cash Equivalents [Line Items]              
Revenue     26,991,000     25,389,000  
Write-down of supplies     1,100,000        
Testing | Revenue recognition              
Cash and Cash Equivalents [Line Items]              
Loss from operations           $ 600,000  
Net income (loss) per common share, basic and diluted (in usd per share) | $ / shares           $ 0.02  
Revenue           $ 600,000  
Biopharmaceutical              
Cash and Cash Equivalents [Line Items]              
Revenue     722,000     4,140,000  
Johnson & Johnson              
Cash and Cash Equivalents [Line Items]              
Receivable from agreement     7,000,000.0        
Contractual proceeds     $ 13,000,000.0        
Percentage of net cash collections, fee     1.00%        
Accounts Receivable, after Allowance for Credit Loss     $ 0       2,000,000.0
Johnson & Johnson | Percepta v.2              
Cash and Cash Equivalents [Line Items]              
Revenue     0     $ 3,800,000 7,000,000.0
Johnson & Johnson | NasaRISK              
Cash and Cash Equivalents [Line Items]              
Revenue             $ 4,000,000.0
AstraZeneca              
Cash and Cash Equivalents [Line Items]              
Revenue     100,000        
Accounts Receivable, after Allowance for Credit Loss     100,000        
Biopharmaceutical Company              
Cash and Cash Equivalents [Line Items]              
Contract agreement, amount     500,000        
Biopharmaceutical Company | Biopharmaceutical              
Cash and Cash Equivalents [Line Items]              
Revenue     $ 300,000        
Over-Allotment Option              
Cash and Cash Equivalents [Line Items]              
Number of shares issued and sold (in shares) | shares 825